180 Life Sciences Current ratio
Quel est le Current ratio de 180 Life Sciences?
Le Current ratio de 180 Life Sciences Corp. est 0.58
Quelle est la définition de Current ratio?
Le ratio actuel est un ratio de liquidité qui mesure si une entreprise dispose ou non de ressources suffisantes pour faire face à ses obligations à court terme.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio des entreprises dans Health Care secteur sur NASDAQ par rapport à 180 Life Sciences
Que fait 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Entreprises avec current ratio similaire à 180 Life Sciences
- Unitil a Current ratio de 0.58
- Troy Income & Growth Trust Plc a Current ratio de 0.58
- Electrotherm (India) a Current ratio de 0.58
- Nuveen S&P 500 Dynamic Overwrite Fund a Current ratio de 0.58
- BlueRock Diamonds PLC a Current ratio de 0.58
- Dekel Agri-Vision plc a Current ratio de 0.58
- 180 Life Sciences a Current ratio de 0.58
- Old Republic International a Current ratio de 0.59
- Pimco Income Strategy Fund II a Current ratio de 0.59
- Esprit a Current ratio de 0.59
- Blue Thunder Mining a Current ratio de 0.59
- International Stem Cell a Current ratio de 0.59
- Cathedra Bitcoin Inc a Current ratio de 0.59